Yokogawa has developed the SU10 Single CellomeTM Unit, a device that uses a nanopipette*1 to inject substances such as genes and drugs and aspirate intracellular materials at target locations in individual cells
– Results published in first paper from 18-month analysis of ongoing pivotal Phase 3 trial were generally consistent with overall
BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.
The World Health Organisation has issued a guideline to keep safety in schools. We have outlined the most important keys
Hutchison China MediTech Limited said on Friday that it got approval from the China’s authority, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), a Priority Review status to the New Drug Application (NDA) for surufatinib, for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (NET).
ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China, which will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.
Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019. Read the full article
EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of
Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch
Vaxess and GC Pharma will collaborate on Influenza vaccine smart release patch, in a deal which will give Vaxess exclusive
Kangpu Biopharmaceuticals doses first humans with KPG-818 for treating SLE and hematological malignancies
Kangpu Biopharmaceuticals has completed a first-in-human phase I single ascending dose (SAD) clinical study in the United States, testing KPG-818 for the treatment of SLE and hematological malignancies.